
|Articles|February 21, 2020
Signals Analytics Expands Rare Disease Data Coverage
Advertisement
Signals Analytics, analytics platform that leverages external data to uncover trends and predictive insights, announced the addition of 1,600 rare diseases, deepening its coverage of medical conditions and therapeutic areas.
The enhancement of rare diseases coverage offers pharmaceutical companies a comprehensive view of this hard-to-capture landscape with relevant insights that can allow opportunities for drug development, repurposing, and partnering.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
2
FDA Announces New Biosimilar-Targeted Draft Guidance
3
Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report
4
Lilly Forms Partnership with NVIDIA to Create AI Supercomputer
5





